Ardelyx (ARDX) Expected to Announce Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX) is projected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $79.40 million for the quarter.

Ardelyx (NASDAQ:ARDX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%. The firm had revenue of $116.13 million for the quarter, compared to analyst estimates of $111.16 million. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Trading Up 0.8 %

Shares of NASDAQ:ARDX opened at $4.85 on Thursday. The company has a current ratio of 4.58, a quick ratio of 4.31 and a debt-to-equity ratio of 0.87. Ardelyx has a 12-month low of $4.02 and a 12-month high of $9.33. The business has a 50 day moving average of $5.07 and a two-hundred day moving average of $5.29. The company has a market capitalization of $1.16 billion, a PE ratio of -30.31 and a beta of 0.81.

Analyst Upgrades and Downgrades

ARDX has been the subject of several analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $5.50 target price on shares of Ardelyx in a research note on Friday, February 21st. Piper Sandler upgraded shares of Ardelyx to a “hold” rating in a research report on Wednesday, March 12th. Raymond James restated a “strong-buy” rating and issued a $13.00 price target (down previously from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $11.00 price target on shares of Ardelyx in a research report on Friday, March 7th. Finally, Jefferies Financial Group cut their price objective on Ardelyx from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, January 2nd. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Ardelyx currently has an average rating of “Moderate Buy” and a consensus target price of $10.61.

Insider Activity

In other Ardelyx news, CEO Michael Raab sold 41,666 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.36, for a total value of $223,329.76. Following the completion of the sale, the chief executive officer now directly owns 1,108,719 shares in the company, valued at $5,942,733.84. This represents a 3.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Mott purchased 77,729 shares of Ardelyx stock in a transaction dated Monday, February 24th. The shares were bought at an average price of $5.00 per share, for a total transaction of $388,645.00. Following the acquisition, the director now owns 2,015,494 shares in the company, valued at approximately $10,077,470. This trade represents a 4.01 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 158,076 shares of company stock worth $823,804 over the last three months. Insiders own 5.90% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.